Safety & Side Effects

Retatrutide Side Effects

Learn about Retatrutide side effects based on clinical trials, including common symptoms, what to expect, and how it compares to existing treatments.

Whether you have read about retatrutide in news coverage and want to understand its side-effect profile, or are following its development from clinical trials towards possible approval, this guide explains what is known about the side effects of retatrutide based on currently published trial data — and what remains uncertain. LetsLoseWeight is an independent comparison site; we do not prescribe medication.

Important: Retatrutide is an investigational medicine. As of this guide's last review, it is not licensed by the MHRA and is not available from regulated UK pharmacies. Its safety profile is therefore being characterised from clinical trial data only — not from the wider real-world experience that exists for licensed medicines like Mounjaro and Wegovy. Anyone offering retatrutide for sale in the UK outside a registered clinical trial is doing so unlawfully. This guide is informational and does not promote use of retatrutide.

What we know — and don't know — about retatrutide's safety

Retatrutide's side-effect profile, at the time of this guide, comes mainly from the phase 2 obesity trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., 2023) and from related phase 2 trials in type 2 diabetes and metabolic dysfunction-associated steatohepatitis. Phase 3 trials (the TRIUMPH programme) are ongoing.

Phase 2 data tells us:

  • The headline frequencies of common side effects in a defined trial population
  • Whether any signals were identified at low frequencies that warranted closer attention in phase 3

Phase 2 data does not yet tell us:

  • The full long-term safety profile in real-world, more diverse populations
  • Whether any rare but serious effects emerge with widespread use
  • How retatrutide compares directly with Mounjaro or Wegovy in head-to-head trials (none has been published)

In short: the picture below is provisional. It will fill in with phase 3 data and post-marketing surveillance, neither of which exists yet.

Common side effects in the phase 2 trial

The reported common side effects of retatrutide in the phase 2 obesity trial were broadly similar to those of other GLP-1 class medicines, dominated by gastrointestinal symptoms:

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation
  • Indigestion

These tended to be most pronounced early in treatment and at higher doses, with most being mild to moderate in severity. The proportion of trial participants who discontinued the trial because of side effects was higher in the higher-dose groups — broadly consistent with the dose-dependence seen with Mounjaro and Wegovy.

Less common observations from the phase 2 trial

The phase 2 obesity trial reported a small number of less common observations, including:

  • Increased heart rate at higher doses — comparable to or slightly greater than what has been seen with other GLP-1-class medicines.
  • Cardiac arrhythmias in a small number of participants in higher-dose groups — flagged as a signal for follow-up in larger trials.
  • Skin reactions at injection sites, similar to those seen with other injectable GLP-1 medicines.

The trial was not large enough or long enough to firmly characterise rare events. Phase 3 trials, which enrol thousands of participants over longer periods, are designed to provide that level of detail.

What's likely, by analogy with Mounjaro and Wegovy

Because retatrutide acts on overlapping hormone receptors (GLP-1, GIP) plus an additional one (glucagon), some of its safety considerations are likely to overlap with those of Mounjaro and Wegovy. By analogy:

  • Acute pancreatitis is a known concern for the GLP-1 medicine class generally; phase 3 trials will look at this in detail.
  • Gallbladder problems are common with rapid weight loss and with this class of medicines; likely to feature in retatrutide's eventual licence too.
  • Thyroid C-cell tumour warnings (MTC, MEN 2) apply to other GLP-1 class medicines because of findings in animal studies; retatrutide regulatory review will address this.
  • Pregnancy and breastfeeding — likely to be contraindicated, in line with other GLP-1 medicines.

These are reasonable expectations rather than confirmed facts for retatrutide specifically. The MHRA licence, when it exists, will be the authoritative reference.

The mechanism that makes retatrutide different — and what it might mean for safety

Retatrutide adds a third receptor target, glucagon, to the GLP-1/GIP combination already used by Mounjaro. Glucagon receptor activation is thought to increase resting energy expenditure and to promote breakdown of stored fat in the liver. This is part of why retatrutide may achieve larger average weight loss than existing options — and also why some side effects might differ.

Specific points to watch in upcoming trials:

  • Heart rate and cardiac effects — glucagon has effects on the heart, and the phase 2 cardiac arrhythmia signal will be examined more carefully in phase 3.
  • Liver function — retatrutide is being studied for fatty liver disease, but liver effects need careful safety assessment.
  • Glycaemic control in type 2 diabetes — the glucagon component theoretically opposes the blood-sugar-lowering effects of GLP-1 and GIP. Trials in diabetes will clarify the net effect.

This is informed speculation, not regulatory guidance. The actual safety profile will only be known after phase 3 readouts.

Why "buying retatrutide for safety reasons" doesn't make sense

Some online sellers position retatrutide as a "next generation" alternative to Mounjaro or Wegovy. From a safety standpoint, this is the opposite of what the evidence supports:

  • No regulatory approval anywhere in the world for retatrutide in obesity at the time of this guide's review.
  • No licensed UK pharmacies can supply it.
  • No clinical-trial-grade safety data apply to product bought outside trials — the vials may not contain retatrutide, may be incorrectly dosed, may be contaminated.
  • No clinical safety net if something goes wrong.

The MHRA has warned consumers about buying weight-loss medicines without a prescription. The same warning applies — with extra force — to medicines that have not been approved at all. Anyone choosing the "newer" option through unregulated supply is taking on every safety risk that licensed medicines protect against, plus the added risk of an unproven product.

When retatrutide might be available

If phase 3 trials succeed, retatrutide will need to:

  1. Receive marketing authorisation from the MHRA
  2. Be assessed by NICE for NHS use
  3. Be supplied through licensed UK pharmacy distribution

Each step takes time. There is no published date. Anyone considering weight-loss treatment now should focus on the medicines that are actually available through regulated UK channels — Mounjaro and Wegovy.

Reporting concerns

Once retatrutide is licensed in the UK, suspected side effects will be reportable through the MHRA Yellow Card scheme. It will, like other newly licensed medicines, carry a black triangle (▼) for additional safety monitoring during its first years of use.

Until then, the only retatrutide use in the UK is within registered clinical trials, where adverse events are reported through the trial's own safety monitoring system to the MHRA.

Frequently asked questions

Are retatrutide's side effects worse than Mounjaro's?
Direct comparison would require a head-to-head trial; none has been published. The phase 2 data suggests overall side-effect rates broadly similar to other GLP-1 class medicines, with possible dose-dependent differences at the highest doses. Until phase 3 results are available, "worse" or "better" is not a defensible claim.

Is the cardiac arrhythmia signal serious?
The phase 2 trial flagged a signal worth watching in larger trials — that is what flags do. It is not the same as a confirmed risk. Phase 3 trials are designed to characterise this in many more patients over longer periods.

Can I get retatrutide in a trial?
Possibly. The TRIUMPH trial programme has been recruiting in some countries. For UK trial sites, see the National Institute for Health and Care Research's Be Part of Research portal. Trial participation is the safest way to access an unlicensed medicine, because it includes proper clinical assessment, safety monitoring, and follow-up.

What if the side effects are worse than Mounjaro's?
That is a real possibility — early-phase data sometimes looks worse on side effects than newer phase 3 data, or vice versa. The benefit/risk balance for each medicine is assessed individually by regulators. If retatrutide is licensed, the MHRA will have judged that the benefits outweigh the risks for the licensed indication; that judgement does not exist yet.

Next steps

Sources

This guide is for general information only and is not a substitute for professional medical advice. Retatrutide is not currently approved or available in the UK outside clinical trials.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Guides
Retatrutide Side Effects: Phase 2 Trial Data UK | LetsLoseWeight